source
- Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trialA Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised a ...Endpoints · 3mo ago↗ source
- UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseasesThe buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.BioPharma Dive · 3mo ago↗ source
- What is your AI drug repurposing strategy missing?Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.BioPharma Dive